What Is KPV and How Does It Work
KPV is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) - just Lysine, Proline, and Valine, the last three residues of the parent hormone. Alpha-MSH itself has well-documented anti-inflammatory activity alongside its pigmentation and appetite effects, which are mediated through melanocortin receptors. KPV's defining feature is that it retains the anti-inflammatory activity of alpha-MSH without those receptor-mediated pigmentation or appetite effects, because at physiologically relevant concentrations it does not meaningfully bind melanocortin receptors at all.
Instead, preclinical research points to a receptor-independent, intracellular mechanism: KPV inhibits NF-kB nuclear translocation and NLRP3 inflammasome activation, which in turn suppresses production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. A notable and somewhat unusual feature for a peptide this small is apparent oral stability - cell and mouse studies suggest KPV can enter intestinal and immune cells via the PepT1 peptide transporter and retain activity when given orally, an uncommon trait since most peptides are broken down by gastric and intestinal proteases before they can act locally.
Research Dosing
No human clinical trial has established a dose for KPV. What follows reflects ranges commonly cited in research-community protocols and practitioner materials, not clinical dosing data - treat it as a hedged reference point, not a directive.
| Route | Commonly Cited Range | Timing | Typical Duration |
|---|---|---|---|
| Oral (enteric-coated) | ~500mcg–1mg | Empty stomach | 4–8 weeks, then reassess |
Context: Enteric coating is commonly used in gut-focused protocols because plain oral KPV is otherwise degraded by stomach acid and gastric peptidases before it reaches the intestine, where the PepT1-mediated uptake mechanism described above is thought to matter most. This is a formulation detail cited in research-community materials, not a claim independently verified by BioStackIQ.
Regulatory Status
KPV is not FDA-approved for any indication, has no USP or NF drug substance monograph, and is not currently on the FDA's 503A Bulks List - the list of bulk substances that registered pharmacies may legally use to compound human drug products. That means there is presently no legal compounding pathway for KPV, regardless of prescriber intent. There is a genuine regulatory development worth flagging accurately: on July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to review several peptide bulk drug substances, including KPV in both free-base and acetate form, and voted to recommend KPV for inclusion on the 503A Bulks List. That vote is advisory only - it is not an FDA approval and does not immediately authorize compounding. The FDA must still proceed through formal notice-and-comment rulemaking before any substance is actually added to the list, and the agency's own scientific staff reportedly did not concur with all of the committee's recommendations. As of this writing, KPV remains sold strictly as a research chemical labeled "not for human consumption," which is the only presently legal basis for retail sale.
What Research Shows
The foundational anti-inflammatory data on KPV comes from cell-culture and mouse models of inflammatory bowel disease, not human trials. In one frequently cited study, KPV was tested in two well-established murine colitis models - DSS-induced colitis and CD45RB(hi) transfer colitis - and treated animals showed earlier recovery, significantly stronger regain of body weight, reduced inflammatory cell infiltration, and significantly lower myeloperoxidase (MPO) activity in colon tissue, a standard marker of intestinal inflammation.
A related line of work from the same research area examined the PepT1 transport mechanism directly, showing that KPV uptake through this transporter reduces intestinal inflammation in cell and animal models. Taken together, this is meaningful and mechanistically coherent preclinical evidence - but it is preclinical. No published human clinical trial has tested KPV for inflammatory bowel disease, skin conditions, or any other indication, so claims about its effects in people remain extrapolations from animal and cell-culture data rather than demonstrated outcomes.
For related gut-focused research protocols, see the BPC-157 protocol guide.